Pantoprazol Stada (Pantoprazole Sodium Sesquihydrate)

Pantoprazol Stada is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related conditions:

• Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of erosive esophagitis.
• Erosive oesophagitis: heals mucosal breaks caused by chronic acid exposure.
• Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence.
• Zollinger‑Ellison syndrome: controls excessive gastric acid secretion in this rare endocrine disorder.

• Pantoprazole selectively and irreversibly binds to the H+/K+‑ATPase enzyme (the gastric proton pump) on the secretory surface of parietal cells. By inhibiting this final step of acid production, it markedly lowers gastric acidity, allowing damaged mucosa to heal and reducing acid‑related symptoms.

Pantoprazol Stada is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhoea: usually self‑limiting.
• Nausea or abdominal discomfort.
• Flatulence or bloating.
• Constipation: occasional.
• Dry mouth.

Serious or Rare Side Effects

• Acute interstitial nephritis: presents with renal impairment and eosinophilia.
• Severe hypersensitivity reactions: including Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Clostridioides difficile‑associated colitis: may cause severe diarrhoea.
• Osteoporotic fractures: long‑term use linked to reduced bone mineral density.
• Hypomagnesemia: low serum magnesium with prolonged therapy.

Before initiating therapy, consider the following precautions:

• Assess renal function: dose adjustment may be required in severe impairment.
• Review concomitant medications: potential for altered absorption of drugs that need an acidic environment.
• Monitor for infection: prolonged acid suppression can increase risk of gastrointestinal infections.
• Evaluate bone health: consider calcium and vitamin D supplementation for long‑term users.
• Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment.
• Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Pantoprazole may affect the pharmacokinetics of several medicines. Awareness of the interaction potential helps optimise therapy.

Major Interactions (Avoid)

• Antifungal agents (ketoconazole, itraconazole): reduced absorption and loss of efficacy.
• HIV protease inhibitors (atazanavir, nelfinavir): markedly decreased plasma concentrations.

Moderate Interactions (Monitor Closely)

• Clopidogrel: possible reduction in antiplatelet effect.
• Warfarin: may enhance anticoagulant response, requiring INR monitoring.
• Methotrexate (high dose): decreased renal clearance, risk of toxicity.
• Digoxin: slight increase in serum levels.
• Oral contraceptives: potential reduction in hormonal efficacy.